DEFUSE 3亚组分析:晚时间窗转运患者血栓切除术结局
该研究为DEFUSE 3试验的亚组分析,纳入182例前循环大血管闭塞、符合影像学错配标准的晚时间窗(6-16小时)卒中患者,比较转运与直接入院患者的血栓切除术疗效。结果显示两组90天改良Rankin量表评分分布及功能独立率无显著差异,转运患者治疗效应未降低,提示转运晚时间窗血栓切除候选者应被鼓励。
要点
- 晚时间窗(6-16小时)符合错配标准的卒中患者中,转运者与直接入院者血栓切除术疗效相当。
- 转运患者90天功能独立率45%,直接入院者44%,治疗效应无显著差异。
- 转运潜在晚时间窗血栓切除候选者与显著临床获益相关,应予以鼓励。
核心结论
- 在经半暗带错配标准筛选的晚时间窗患者中,转运患者的良好结局率和治疗效应均未下降。
研究设计与样本
- DEFUSE 3试验的亚组分析,为前瞻性、随机、多中心、盲法终点试验,纳入美国38个卒中中心的182例患者。
- 患者为前循环大血管闭塞、初始梗死体积<70 mL、错配比≥1.8、错配体积≥15 mL,且距最后已知良好时间6-16小时。
- 患者按直接入院或从初级中心转运分层,随机接受血管内血栓切除术联合标准药物治疗或单独标准药物治疗。
主要发现
- 转运患者占66%,直接入院者占34%;转运组中位年龄71岁(IQR 60-79),直接组70岁(IQR 59-80)。
- 血栓切除组总体功能独立率(90天mRS 0-2)无差异(直接44% vs 转运45%),治疗效应也无差异(直接OR 2.0,95%CI 0.9-4.4 vs 转运OR 3.1,95%CI 1.6-6.1)。
- 血栓切除再灌注率、死亡率和症状性颅内出血率均无差异。
临床怎么用
- 对于符合DEFUSE 3影像学筛选标准的晚时间窗(6-16小时)卒中患者,转运至有能力行血栓切除术的中心与直接入院同样有效,应鼓励转运潜在候选者。
局限性
- 本研究为DEFUSE 3试验的亚组分析,样本量有限,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Although thrombectomy benefit was maintained in transfer patients with ischemic stroke in early-window trials, overall functional independence rates were lower in thrombectomy and medical management-only groups. OBJECTIVE: To evaluate whether the imaging-based selection criteria used in the Endovascular Therapy Following Imaging Evaluation for Ischemic Stroke 3 (DEFUSE 3) trial would lead to comparable outcome rates and treatment benefits in transfer vs direct-admission patients. DESIGN, SETTING, AND PARTICIPANTS: Subgroup analysis of DEFUSE 3, a prospective, randomized, multicenter, blinded-end point trial. Patients were enrolled between May 2016 and May 2017 and were followed up for 90 days. The trial comprised 38 stroke centers in the United States and 182 patients with stroke with a large-vessel anterior circulation occlusion and initial infarct volume of less than 70 mL, mismatch ratio of at least 1.8, and mismatch volume of at least 15 mL, treated within 6 to 16 hours from last known well. Patients were stratified based on whether they presented directly to the study site or were transferred from a primary center. Data were analyzed between July 2018 and October 2018. INTERVENTIONS OR EXPOSURES: Endovascular thrombectomy plus standard medical therapy vs standard medical therapy alone. MAIN OUTCOMES AND MEASURES: The primary outcome was the distribution of 90-day modified Rankin Scale scores. RESULTS: Of the 296 patients who consented, 182 patients were randomized (66% were transfer patients and 34% directly presented to a study site). Median age was 71 years (interquartile range [IQR], 60-79 years) vs 70 years (IQR, 59-80 years); 69 transfer patients were women (57%) and 23 of the direct group were women (37%). Transfer patients had longer median times from last known well to study site arrival (9.43 vs 9 hours) and more favorable collateral profiles (based on hypoperfusion intensity ratio): median for transfer, 0.35 (IQR, 0.18-0.47) vs 0.42 (IQR, 0.25-0.56) for direct (P = .05). The primary outcome (90-day modified Rankin Scale score shift) did not differ in the direct vs transfer groups (direct OR, 2.9; 95% CI, 1.2-7.2; P = .01; transfer OR, 2.6; 95% CI, 1.3-4.8; P = .009). The overall functional independence rate (90-day modified Rankin Scale score 0-2) in the thrombectomy group did not differ (direct 44% vs transfer 45%) nor did the treatment effect (direct OR, 2.0; 95% CI, 0.9-4.4 vs transfer OR, 3.1; 95% CI, 1.6-6.1). Thrombectomy reperfusion rates, mortality, and symptomatic intracranial hemorrhage rates did not differ. CONCLUSIONS AND RELEVANCE: In late-window patients selected by penumbral mismatch criteria, both the favorable outcome rate and treatment effect did not decline in transfer patients. These results have health care implications indicating transferring potential candidates for late-window thrombectomy is associated with substantial clinical benefits and should be encouraged. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT02586415.
引用
- Sarraj A, Mlynash M, Savitz SI, et al. Outcomes of Thrombectomy in Transferred Patients With Ischemic Stroke in the Late Window: A Subanalysis From the DEFUSE 3 Trial. JAMA Neurol. 2019. PMID: 30734042. doi:10.1001/jamaneurol.2019.0118
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。